• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
Report on New Patented Drugs — Olmetec Application of the
Report on New Patented Drugs — Olmetec Application of the

... The publication of Summary Reports is part of the PMPRB’s commitment to make its price review process more transparent. Where comparators and dosage regimens are referred to in the Summary Reports, they have been selected by the HDAP for the purpose of carrying out the PMPRB’s regulatory mandate, wh ...
File
File

... Risk cannot be ruled out ...
STATUS DECISION OF CONTROLLED AND NON
STATUS DECISION OF CONTROLLED AND NON

Photoreactivity of drugs
Photoreactivity of drugs

... number of effects in cells and tissue, like destruction of the plasma membrane, lysosomes and tubuli, induction of apoptosis by oxidative stress and destruction of tumour blood vessels leading to tumour suffocation. Finding optimal sensitizers and drug delivery systems is crucial in improving the ef ...
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring

. -- 1
. -- 1

... which would be established by toxicological data, worst case or other appropriate methods to predict effects, analyses, including chronic and subchronic effects on humans and other ...
Content and Format of an Investigational New Drug (IND) Application
Content and Format of an Investigational New Drug (IND) Application

... An IND application is submitted for a specific drug substance and may incorporate multiple clinical protocols corresponding the various phases of the evaluation of its safety and effectiveness. The clinical investigation of a previously untested drug is typically divided into three phases. Although ...
Starpharma to Conduct Animal Trials on Vaginal Microbicide Clover
Starpharma to Conduct Animal Trials on Vaginal Microbicide Clover

The Why and How of Absorption, Distribution, Metabolism, Excretion
The Why and How of Absorption, Distribution, Metabolism, Excretion

... inadequate distribution and/or rapid metabolism, leading to too low drug concentrations at the target site.8 And since toxicity is also a major factor of attrition, the development of compounds is often halted even before a detailed human pharmacokinetics or efficacy study can be performed. Hence, t ...
ADULTERATION OF HERBAL MEDICINES AND DIETARY SUPPLEMENTS WITH UNDECLARED
ADULTERATION OF HERBAL MEDICINES AND DIETARY SUPPLEMENTS WITH UNDECLARED

... manufacturing practices (GMPs) are not strictly applied in its manufacturing process. Besides, herbal and traditional medicines may contain many pharmacologically active chemicals from different parts of several plants. Therefore, it is very difficult to monitor how many chemicals are present in a p ...
Synthetic Biology: Does Re-Writing Nature Require Re
Synthetic Biology: Does Re-Writing Nature Require Re

MEMORANDUM Date: April 9, 2012 To: Vancomycin File From
MEMORANDUM Date: April 9, 2012 To: Vancomycin File From

OF HEALTH  &  HUMAN  SERVICES Ms. Anna Tucci
OF HEALTH & HUMAN SERVICES Ms. Anna Tucci

... sectionsimmediately preceding and following section 35O(c)(l)(B)(ii). Section 35O(c)(l)(B)(i) statesthat the vitamin must be intended for ingestion in tablet, capsule or liquid form. Each of these forms denotesa method of ingestion that involves \ swallowing into the stomach. Section 350(c)(2) state ...
Pharmacology Basics
Pharmacology Basics

... The user is able to break down and/or excrete the drug more quickly due to repeated exposure. Increased excretion ...
Process Pharmacology: A Pharmacological Data Science Approach
Process Pharmacology: A Pharmacological Data Science Approach

... the intermediates. This moves targets from the focus of classical pharmacological concepts to the link between drugs and biological processes. These processes become the main therapeutic focus. The necessary associations of drugs with targets, drug targets with genes, and genes with biological proce ...
Memorandum of  Meeting  Minutes Meeting  Date: February  15,2002
Memorandum of Meeting Minutes Meeting Date: February 15,2002

... The Agency suggested that a more expeditious way to get the reformulated product to market may be to file a 505(b)(2) NDA. However, this application would need to include a stability profile, normally required under an NDA. Bayer noted that it had 6 products that would be reformulated to contain phe ...
study on identification and assessment of drug interactions in
study on identification and assessment of drug interactions in

... administration of a drug combination that is different from the anticipated known effects of the two agents when given alone and that can result in reduced effectiveness or increased toxicity1. A DDI can be the consequence of various situations that reflect the growing number of drugs available in t ...
Pharmacology 120
Pharmacology 120

... Over-The-Counter (OTC) Meds • Over-the-counter (OTC) drugs are products that are available without a prescription for self-treatment of various problems – Many patients do not report use of OTC meds, as they do not consider them to be “real medicines”; health care workers must ask about their use! – ...
Memorandum
Memorandum

... botanical Momordicu charuntiu L. Pleasenote the difference in the Latin binomial names for your botanical ingredient and the botanical cited in the article. The article primarily focuses on general efficacy, and not the safety of the seedsor juice of the plant. It does not address the specific plant ...
Pharmacokinetics_200..
Pharmacokinetics_200..

... • requires absorption • Administration of larger volumes than s.c.; drug can be released slowly into the circulation, while some of it being stored in the muscle • Antibiotics usually given this way • often used as depot preparations (slow diffusion from lipid medium – e.g. haloperidol decanoate) ...
Print / Save PDF - Pennsylvania Patient Safety Authority
Print / Save PDF - Pennsylvania Patient Safety Authority

... of the terms for the many different kinds of longacting formulations. As a result, there are many inconsistencies, allowing different suffixes to be used for an identical formulation by two different manufacturers or even similar suffixes for dissimilar formulations. In short, the nomenclature used ...
Exam Sample-1
Exam Sample-1

... c) bioisostere for –CH2d) increasing solubility of the drug e)none of the above ...
Human abuse potential study design and interpretation for CNS
Human abuse potential study design and interpretation for CNS

Basic Principles of GMP - World Health Organization
Basic Principles of GMP - World Health Organization

... US legislative actions: more clinical data in children  US provision in the 1997 Food and Drug Administration (FDA) Modernisation Act. The American "pediatric exclusivity" provision provides a 6 month patent extension for companies willing to perform paediatric clinical investigations at the reque ...
nderzko - Harvard DASH
nderzko - Harvard DASH

... determines how drugs should be labeled and what kind of advertising can accompany the sale of drugs. The FDA also controls the dissemination of drugs. In fact, product labeling is what led to ...
< 1 ... 112 113 114 115 116 117 118 119 120 ... 193 >

Biosimilar

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is a copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original ""innovator"" products, and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and may be quite sensitive to changes in manufacturing processes. Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, nor to the exact fermentation and purification process, nor to the active drug substance. They do have access to the commercialized innovator product.Drug related authorities such as European Medicines Agency (EMA), Food and Drug Administration (FDA), and Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; animal studies (including the assessment of toxicity); and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product.In case of a monoclonal antibody-containing medicinal product, such as Remsima, extensive physicochemical and biological characterization for it and its reference product Remicade was conducted in order to demonstrate their highly similar properties. Consequently, EMA have granted a marketing authorisation for only a few numbers of biosimilars since 2006 including a monoclonal antibody which is recently approved. Meanwhile, on March 6, 2015, the FDA approved the United States's first biosimilar product, the biosimilar filgrastim Zarxio.
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report